Revelation Biosciences (NASDAQ:REVB) Releases Quarterly Earnings Results, Misses Expectations By $1.56 EPS

Revelation Biosciences (NASDAQ:REVB) issued its quarterly earnings data on Thursday. The company reported ($2.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($1.56), FiscalAI reports.

Revelation Biosciences Stock Performance

REVB stock traded down $0.06 during midday trading on Friday, reaching $0.96. The company’s stock had a trading volume of 224,262 shares, compared to its average volume of 76,426. The stock has a fifty day simple moving average of $1.20 and a two-hundred day simple moving average of $2.60. The firm has a market capitalization of $3.57 million, a price-to-earnings ratio of -0.02 and a beta of -0.14. Revelation Biosciences has a 1 year low of $0.95 and a 1 year high of $40.08.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Revelation Biosciences stock. Armistice Capital LLC raised its holdings in Revelation Biosciences, Inc. (NASDAQ:REVB) by 442.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 434,272 shares of the company’s stock after purchasing an additional 354,272 shares during the period. Armistice Capital LLC owned about 6.29% of Revelation Biosciences worth $347,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.80% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Revelation Biosciences has an average rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.